Annals of Laboratory Medicine

Korean Society for Laboratory Medicine (대한진단검사의학회)
권호 표지
DOI QR코드

DOI QR Code

Emergence of BCR-ABL1 (p190) in Acute Myeloid Leukemia Post-Gilteritinib Therapy

  • Heejeong Kim (Department of Laboratory Medicine, Pusan National University School of Medicine, Biomedical Research Institute, Pusan National University Hospital) ;
  • In-suk Kim (Department of Laboratory Medicine, Pusan National University School of Medicine, Pusan National University Yangsan Hospital) ;
  • Hyerim Kim (Department of Laboratory Medicine, Pusan National University School of Medicine, Biomedical Research Institute, Pusan National University Hospital)
  • Received : 2022.09.18
  • Accepted : 2022.12.29
  • Published : 2023.07.01
Download PDF
⟨ Previous Next ⟩

Abstract

Keywords

Acknowledgement

This work was supported by a clinical research grant from Pusan National University Hospital in 2022.

References

  1. Papaemmanuil E, Gerstung M, Bullinger L, Gaidzik VI, Paschka P, Roberts ND, et al. Genomic classification and prognosis in acute myeloid leukemia. N Engl J Med 2016;374:2209-21. https://doi.org/10.1056/NEJMoa1516192
  2. Daver N, Schlenk RF, Russell NH, Levis MJ. Targeting FLT3 mutations in AML: review of current knowledge and evidence. Leukemia 2019;33:299-312. https://doi.org/10.1038/s41375-018-0357-9
  3. Pulte ED, Norsworthy KJ, Wang Y, Xu Q, Qosa H, Gudi R, et al. FDA approval summary: gilteritinib for relapsed or refractory acute myeloid leukemia with a FLT3 mutation. Clin Cancer Res 2021;27:3515-21. https://doi.org/10.1158/1078-0432.CCR-20-4271
  4. McMahon CM, Ferng T, Canaani J, Wang ES, Morrissette JJD, Eastburn DJ, et al. Clonal selection with RAS pathway activation mediates secondary clinical resistance to selective FLT3 inhibition in acute myeloid leukemia. Cancer Discov 2019;9:1050-63. https://doi.org/10.1158/2159-8290.CD-18-1453
  5. Piloto O, Wright M, Brown P, Kim KT, Levis M, Small D. Prolonged exposure to FLT3 inhibitors leads to resistance via activation of parallel signaling pathways. Blood 2007;109:1643-52. https://doi.org/10.1182/blood-2006-05-023804
  6. Kropp EM and Li Q. Mechanisms of resistance to targeted therapies for relapsed or refractory acute myeloid leukemia. Exp Hematol 2022;111:13-24. https://doi.org/10.1016/j.exphem.2022.04.001
  7. Swerdlow SH, Campo E, et al. eds. World Health Organization classification of tumours of haematopoietic and lymphoid tissues. Revised 4th ed. Lyon: IARC, 2017.
  8. Alotaibi AS, Yilmaz M, Loghavi S, DiNardo C, Borthakur G, Kadia TM, et al. Emergence of BCR–ABL1 fusion in AML post-FLT3 inhibitor-based therapy: a potentially targetable mechanism of resistance – a case series. Front Oncol 2020;10:588876. https://doi.org/10.3389/fonc.2020.588876
  9. Staudt D, Murray HC, McLachlan T, Alvaro F, Enjeti AK, Verrills NM, et al. Targeting oncogenic signaling in mutant FLT3 acute myeloid leukemia: the path to least resistance. Int J Mol Sci 2018;19:3198. https://doi.org/10.3390/ijms19103198